CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
Injection of AAV2-REP1 (10e11 vg)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02553135
NCT02553135Phase 2Completed
CompareCT.gov

An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)

Byron Lam·interventional·Posted Sep 17, 2015·Updated Jul 29, 2019

In Brief

A Phase 2 clinical trial evaluating Injection of AAV2-REP1 (10e11 vg) for Choroideremia. Completed, enrolled 6 participants across 1 site.

Detailed Summary

Phase II gene therapy study, involving a total of 6 male patients with choroideremia. The study will be conducted at the Bascom Palmer Eye Institute, University of Miami. Patients will be required to attend a total of 11 study visits over a 24 month period with an additional 3 year follow-up.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChoroideremia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 17, 2015
Enrollment StartSep 1, 2015
Primary CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.8 years ago

Interventions

Injection of AAV2-REP1 (10e11 vg)biological

Single Group: single arm study